Nothing Special   »   [go: up one dir, main page]

PT2513058T - Métodos de síntese de inibidores do fator xa - Google Patents

Métodos de síntese de inibidores do fator xa

Info

Publication number
PT2513058T
PT2513058T PT108014952T PT10801495T PT2513058T PT 2513058 T PT2513058 T PT 2513058T PT 108014952 T PT108014952 T PT 108014952T PT 10801495 T PT10801495 T PT 10801495T PT 2513058 T PT2513058 T PT 2513058T
Authority
PT
Portugal
Prior art keywords
inhibitors
methods
synthesizing factor
synthesizing
factor
Prior art date
Application number
PT108014952T
Other languages
English (en)
Inventor
Pandey Anjali
P T Leitao Emilia
Rato Jose
Jake Song Zhiguo
Original Assignee
Millennium Pharm Inc
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Portola Pharm Inc filed Critical Millennium Pharm Inc
Publication of PT2513058T publication Critical patent/PT2513058T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT108014952T 2009-12-17 2010-12-15 Métodos de síntese de inibidores do fator xa PT2513058T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28768009P 2009-12-17 2009-12-17

Publications (1)

Publication Number Publication Date
PT2513058T true PT2513058T (pt) 2017-01-26

Family

ID=43532100

Family Applications (1)

Application Number Title Priority Date Filing Date
PT108014952T PT2513058T (pt) 2009-12-17 2010-12-15 Métodos de síntese de inibidores do fator xa

Country Status (10)

Country Link
US (2) US8394964B2 (pt)
EP (1) EP2513058B1 (pt)
JP (2) JP5766204B2 (pt)
CN (2) CN104774176A (pt)
AR (1) AR079491A1 (pt)
CA (1) CA2784904C (pt)
ES (1) ES2610145T3 (pt)
PT (1) PT2513058T (pt)
TW (1) TW201144283A (pt)
WO (1) WO2011084519A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101595092B (zh) * 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
JP5766204B2 (ja) * 2009-12-17 2015-08-19 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の合成方法
TW201221128A (en) * 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
WO2013033370A1 (en) * 2011-08-31 2013-03-07 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104341343B (zh) * 2013-07-24 2018-09-28 四川海思科制药有限公司 贝曲西班的晶型及其制备方法和用途
CN105017078B (zh) * 2014-04-23 2017-02-15 中国科学院大连化学物理研究所 一种芳香醛催化转化制备亚胺酸酯的方法
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
US10308619B2 (en) * 2015-06-23 2019-06-04 Covestro Deutschland Ag Substituted triazines and a method for producing same
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN106995405A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种贝曲西班马来酸盐无定型物及其制备方法
CN107098853A (zh) * 2016-02-20 2017-08-29 天津科伦药物研究有限公司 贝曲西班马来酸盐的制备方法
CN105732490A (zh) * 2016-03-25 2016-07-06 重庆医科大学 一种贝曲西班的制备方法
US20190300483A1 (en) * 2016-06-02 2019-10-03 Dr. Reddy's Laboratories Limited POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
EP3254674A1 (en) 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
WO2018042320A1 (en) * 2016-08-30 2018-03-08 Dr. Reddy’S Laboratories Limited Salts of betrixaban and processes for preparation thereof
CN107778223B (zh) * 2016-08-31 2020-05-15 鲁南制药集团股份有限公司 一种马来酸贝曲西班的制备方法
KR102031186B1 (ko) * 2017-01-11 2019-11-08 주식회사 엘지생활건강 단백질 강도 강화용 조성물
CN107868039A (zh) * 2017-11-27 2018-04-03 中国药科大学 一种贝曲沙班中间体n－（5－氯－2－吡啶基）－2－［（4－氰基苯甲酰基）氨基］－5－甲氧基苯甲酰胺的制备方法
CN112313240A (zh) * 2018-07-27 2021-02-02 优美科股份公司及两合公司 用于制造半导体元件或电子存储器的有机金属化合物
CN114057607A (zh) * 2020-07-29 2022-02-18 鲁南制药集团股份有限公司 一种贝曲西班中间体化合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1302292A (zh) 1998-03-19 2001-07-04 味之素株式会社 氨基异喹啉衍生物
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
WO2001064643A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
US7312235B2 (en) 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
US7122557B2 (en) * 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
DE602004024910D1 (de) 2003-10-09 2010-02-11 Millennium Pharm Inc Thioethersubstituierte benzamide als inhibitoren von faktor xa
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
PT1948608E (pt) 2005-11-08 2012-05-24 Millennium Pharm Inc Novos sais farmacêuticos e polimorfos de um inibidor do fator xa
CA2651303A1 (en) 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN101595092B (zh) * 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
EP2101760B1 (en) 2006-12-08 2013-02-27 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
US20080293704A1 (en) 2007-01-05 2008-11-27 Millennium Pharmaceuticals, Inc. FACTOR Xa INHIBITORS
US20080254036A1 (en) 2007-04-13 2008-10-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
US20110160250A1 (en) 2009-12-17 2011-06-30 Millennium Pharmaceuticals, Inc. Crystalline forms of a factor xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
JP5766204B2 (ja) * 2009-12-17 2015-08-19 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の合成方法
WO2011084652A2 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor

Also Published As

Publication number Publication date
CN102762538B (zh) 2015-11-25
AR079491A1 (es) 2012-02-01
CA2784904A1 (en) 2011-07-14
ES2610145T3 (es) 2017-04-26
TW201144283A (en) 2011-12-16
JP2015091840A (ja) 2015-05-14
WO2011084519A1 (en) 2011-07-14
JP2013514380A (ja) 2013-04-25
CA2784904C (en) 2017-10-10
CN102762538A (zh) 2012-10-31
CN104774176A (zh) 2015-07-15
US8394964B2 (en) 2013-03-12
US8987463B2 (en) 2015-03-24
EP2513058B1 (en) 2016-11-09
EP2513058A1 (en) 2012-10-24
JP5766204B2 (ja) 2015-08-19
US20130211094A1 (en) 2013-08-15
US20110319627A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
PT2513058T (pt) Métodos de síntese de inibidores do fator xa
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
EP2510089A4 (en) SYNTHESIS OF PRAZOL COMPOUNDS
EP2297174A4 (en) EXCLUSIVE SYNTHESIS OF GALACTOSIDE INHIBITORS
EP2438246A4 (en) CONSTRUCTION ASPECTS
ZA201300004B (en) Cyrstalline form of benzylbenzene sglt2 inhibitor
GB2484602B (en) Method of manufacture of acoustic reflectors
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL2506840T3 (pl) Zastosowania inhibitorów czynnika indukowalnego niedotlenieniem
HK1167654A1 (en) Dihydropyrrolonaphtyridinone compounds as inhibitors of jak jak dihydropyrrolonaphtyridinone
EP2507219A4 (en) SYNTHESIS OF SYRBACTINE PROTEASOMMER
PL2473549T3 (pl) Sposób otrzymywania fluorokarbofunkcyjnych silseskwioksanów
IL222474A0 (en) Method of synthesis
IL217756A0 (en) Inhibitors of jnk
EP2467140A4 (en) METHOD FOR CANCER TREATMENT
IL210106A0 (en) Methods of synthesis of morphinans
EP2501803A4 (en) PROCESS FOR PLURIPOTENZINTENSIVATION
EP2478359A4 (en) METHOD FOR IDENTIFYING ANTI-INFLAMMATORY COMPOUNDS
SI2504309T1 (sl) Sinteza acetokslacetaldehida
EP2346829A4 (en) INHIBITORS OF STAT3
GB0808286D0 (en) Inhibitors of HSP90
GB0908609D0 (en) New use of isoQC inhibitors
HK1181031A1 (zh) 合成方法
GB0903651D0 (en) Inhibitors of glyoxalase